CSL vs GRFS: Which Is the Better Buy in 2026?

Last updated October 2026

Short answer

CSL is the larger of the two ($13.26B market cap): the incumbent the market prices for continued execution (13.94x forward earnings, beta 0.83). GRFS is the smaller challenger ($5.20B), cheaper on forward earnings (5.30x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

CSL vs GRFS: the tie-breaker metrics

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Metric	CSL	GRFS	What it tells you
Market cap	$13.26B	$5.20B	Size. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E	13.94	5.30	Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E	18.98	9.79	Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta	0.83	1.20	Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range	29% of range	23% of range	Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book	8.20	1.67	How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: GRFS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how CSL and GRFS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. CSL and GRFS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined CSL and GRFS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Carlisle Companies Incorporated (CSL) do?

Carlisle Companies Incorporated (NYSE: CSL) is a diversified manufacturer that, after years of portfolio reshaping, has become a focused supplier of building-envelope products that make commercial and residential buildings more energy efficient. It operates through two segments: Carlisle Construction Materials (CCM), which makes single-ply roofing membranes (EPDM rubber, TPO, and PVC), polyiso insulation, and metal roofing and wall systems, and Carlisle Weatherproofing Technologies (CWT), which makes waterproofing, air and vapor barriers, sealants, spray polyurethane foam, coatings, and related moisture-protection products. The company earns most of its revenue from commercial construction, and within that, a large share comes from re-roofing (replacing aging roofs), which is more stable than new construction because roofs wear out on a predictable cycle regardless of the economy.

Full CSL guide

What does Grifols (GRFS) do?

Grifols, S.A. is a Spanish healthcare company founded in Barcelona in 1909 and one of the three dominant players in the global blood-plasma industry, alongside CSL and Takeda. It collects human plasma through a large network of donation centers (heavily concentrated in the United States) and fractionates it into therapies, most importantly immunoglobulins (IVIG and subcutaneous Ig) used for immune deficiencies and neurological conditions, plus albumin, alpha-1 antitrypsin, and clotting factors. The business also includes a diagnostics division (blood typing, transfusion screening) and a bio-supplies arm. Revenue comes from selling these plasma-derived medicines to hospitals, specialty pharmacies, and health systems worldwide, with the immunoglobulin franchise the single largest and fastest-growing driver. Grifols trades on the Spanish exchanges under Class A (GRF) and non-voting Class B (GRF.P) shares, and in the US as ADRs under the ticker GRFS.

Full GRFS guide

CSL vs GRFS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

CSL drivers: Commercial re-roofing replacement cycle; Margin expansion and pure-play focus.
GRFS drivers: Immunoglobulin demand and volume growth; Margin recovery from lower cost-per-liter.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes. For GRFS, grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation.

CSL or GRFS: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick CSL if you believe its drivers more; GRFS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the CSL and GRFS guides.

CSL vs GRFS: the full fundamentals

CSL. Carlisle now trades near 19x trailing earnings and about 14x forward, below the low-20s multiple it carried earlier in 2026, as the share price has gone roughly sideways while earnings estimates held up. Investors still focus on adjusted EBITDA margin, free cash flow (about $670 million trailing) and the pace of buybacks rather than raw revenue growth, which swings with weather and construction cycles. Third-quarter results arrive October 28, 2026, with consensus near $5.91 in EPS on about $1.42 billion of revenue, and analysts expect about $21.09 of EPS for full-year 2026.

GRFS. As of October 16, 2026 the ADR trades near $7.72, about 10x trailing and 5x forward earnings and roughly 0.7x sales, a deeper discount to plasma peers like CSL than in mid-2026 after a weak second quarter. The low forward multiple rests on analysts expecting 2026 EPS growth of about 35% and 2027 growth of about 24%, while roughly EUR 9.4 billion of debt means much of the enterprise value still sits with lenders, which is why deleveraging remains the key equity lever. The two analysts in Yahoo's consensus rate the ADR a buy with a mean target near $10.86.

Headline figures (approximate, October 2026): CSL shows revenue (ttm) ~$5.1 billion, revenue growth (q2 2026, yoy) ~8%, q2 2026 adjusted eps ~$7.03 vs ~$6.35 consensus, margins (ttm gross / operating / net) ~35% / ~23% / ~14%; GRFS shows revenue (ttm) ~EUR 7.4 billion (Q2 2026 ~-0.9% YoY), net income (ttm) ~EUR 452 million (FY2025 ~EUR 402 million), q2 2026 eps vs estimate ~$0.17 vs ~$0.28 (miss), gross / operating margin (ttm) ~37.8% / ~15.9%.

The bottom line: CSL vs GRFS

CSL and GRFS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined CSL and GRFS exposure against your real portfolio. It is not an investment adviser.

Wondering how CSL or GRFS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Investing in Carlisle Companies Incorporated with AI

Connect the broker you already use and ask Walnut's AI how CSL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.

Does CSL fit me?

FAQ

What is the difference between CSL and GRFS?

Is CSL or GRFS the better stock?

Neither is universally better. CSL is the larger incumbent; GRFS is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, CSL or GRFS?

On forward P/E (as of October 2026), CSL trades at 13.94x and GRFS at 5.30x, so GRFS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both CSL and GRFS?

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of CSL vs GRFS?

CSL: Carlisle's end markets are cyclical: commercial and residential construction activity is sensitive to interest rates, credit availability, and the broader economy, and a downturn in construction spending would pressure volumes. Revenue can swing on weather, as seen in Q1 2026 when unfavorable winter conditions limited contractors' days on the roof and helped push revenue down about 4% year over year. The business is exposed to raw-material and energy cost inflation (chemicals, membranes, insulation feedstocks) and to destocking or restocking cycles in its distribution channel that can amplify demand swings. Competition in single-ply roofing is intense, with large rivals such as Holcim (owner of Firestone and Duro-Last), GAF, and Johns Manville. Finally, much of Carlisle's growth story depends on continued margin expansion and disciplined capital allocation, so any slippage in pricing power or a misstep in M&A could weigh on the shares. The balance sheet carries about $2.9 billion of debt against about $665 million of cash, and debt-funded buybacks leave less cushion if a construction slowdown arrives; the shares have also traded as low as about $293 in the past year. GRFS: Grifols carries a heavy debt load, with leverage still above 4x, so its equity value is sensitive to interest rates, refinancing terms, and any stumble in cash generation. Governance and accounting scrutiny remains a live overhang: the January 2024 Gotham City short report questioned the company's related-party consolidation (Scranton) and internal controls, and while the company rejected the allegations, the episode damaged trust and the discount has not fully closed. The plasma business is capital-intensive and exposed to donor-supply fluctuations, regulatory oversight (FDA and EMA), and pricing pressure as competitors including CSL and Takeda discount immunoglobulins. As a US-listed ADR of a euro-reporting company, GRFS is also exposed to EUR/USD currency swings, and a failed or lowball takeover attempt could weigh on sentiment. The company has prioritized debt reduction over shareholder returns, so the dividend cushion is thin (a trailing yield near 1.4% on the ADR). Recent execution has been uneven: second-quarter 2026 earnings per share fell well short of the consensus and revenue was roughly flat, and the ADR is down about 16.5% in 2026 as of October 16.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell CSL or GRFS; figures are approximate and dated (as of October 2026). Verify current data before investing.